| 陈 申,马 锐.化疗在晚期非小细胞肺癌治疗中的地位和价值[J].中国肿瘤,2015,24(9):737-741. |
| 化疗在晚期非小细胞肺癌治疗中的地位和价值 |
| The Status and Value of Chemotherapy in Advanced Non-small Cell Lung Cancer |
| 投稿时间：2015-05-03 |
| DOI：10.11735/j.issn.1004-0242.2015.09.A006 |
|
 |
| 中文关键词: 非小细胞肺癌 靶向治疗 化疗 |
| 英文关键词:non-small cell lung cancer targeted therapy chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 1934 |
| 全文下载次数: 985 |
| 中文摘要: |
| 摘 要：化疗于晚期非小细胞肺癌治疗依然具有举足轻重的作用。以IPASS研究为代表的一系列靶向治疗与化疗头对头对比研究，也证实了化疗依旧是EGFR野生型及突变未明患者一线治疗的首要选择。DELTA研究及CTONG0806研究结果则表明二线治疗中化疗比靶向治疗疗效更优。而LUX-LUNG3/6研究生存数据则表明21外显子突变患者可能更适合于一线化疗。总而言之，化疗是晚期非小细胞肺癌治疗全程管理中不可或缺的。 |
| 英文摘要: |
| Abstract：Today，chemotherapy for advanced non-small cell lung cancer is still playing an important role. Represented by IPASS study， a series of RCT research between targeted therapy and chemotherapy confirmed that the chemotherapy remains the first choice for first-line patients with wild type EGFR or uncertain mutation. DELTA and CTONG0806 study results showed that the response with second-line chemotherapy was superior to that with targeted therapy. LUX - LUNG3/6 study results showed that patients with 21 exon mutation might be more suitable first-line chemotherapy. To sum up，chemotherapy is indispensable to the whole course of management for advanced non-small cell lung cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |